# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractor...
The U.S. Supreme Court supports pharmaceutical companies, led by AstraZeneca, in a lawsuit accusing them of funding terrorism i...
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...
The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older w...
The solution, which includes the VENTANA DP 200 slide scanner, Roche's digital pathology workflow software and a display,...
– The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or r...
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.
Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market l...
– Priority Review recognizes the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new t...